KR102856276B1 - 신경변성 질환의 치료를 위한 2-플루오린화된 담즙산 - Google Patents
신경변성 질환의 치료를 위한 2-플루오린화된 담즙산Info
- Publication number
- KR102856276B1 KR102856276B1 KR1020217019166A KR20217019166A KR102856276B1 KR 102856276 B1 KR102856276 B1 KR 102856276B1 KR 1020217019166 A KR1020217019166 A KR 1020217019166A KR 20217019166 A KR20217019166 A KR 20217019166A KR 102856276 B1 KR102856276 B1 KR 102856276B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- general formula
- dihydroxy
- acid
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1820887.6 | 2018-12-20 | ||
| GBGB1820887.6A GB201820887D0 (en) | 2018-12-20 | 2018-12-20 | Compounds |
| PCT/GB2019/053665 WO2020128514A1 (en) | 2018-12-20 | 2019-12-20 | 2-fluorinated bile acids for the treatment of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210125982A KR20210125982A (ko) | 2021-10-19 |
| KR102856276B1 true KR102856276B1 (ko) | 2025-09-05 |
Family
ID=65364420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217019166A Active KR102856276B1 (ko) | 2018-12-20 | 2019-12-20 | 신경변성 질환의 치료를 위한 2-플루오린화된 담즙산 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220073557A1 (https=) |
| EP (1) | EP3898645B1 (https=) |
| JP (1) | JP7503063B2 (https=) |
| KR (1) | KR102856276B1 (https=) |
| CN (1) | CN113330020B (https=) |
| AU (1) | AU2019411556B2 (https=) |
| BR (1) | BR112021011189A2 (https=) |
| CA (1) | CA3123333A1 (https=) |
| EA (1) | EA202191521A1 (https=) |
| ES (1) | ES3036094T3 (https=) |
| GB (1) | GB201820887D0 (https=) |
| IL (1) | IL284093B2 (https=) |
| MX (1) | MX2021007551A (https=) |
| SG (1) | SG11202105465WA (https=) |
| WO (1) | WO2020128514A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4486318A4 (en) * | 2022-03-02 | 2026-02-25 | Boyce Thompson Institute For Plant Res Inc | Cysteamides, related therapeutic compositions and associated processes |
| GB202208151D0 (en) | 2022-06-01 | 2022-07-13 | Nzp Uk Ltd | Compounds |
| GB202314563D0 (en) | 2023-09-22 | 2023-11-08 | Nzp Uk Ltd | Compounds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036379A2 (en) | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| WO2016145216A1 (en) | 2015-03-10 | 2016-09-15 | Metselex, Inc. | Fluorinated and alkylated bile acids |
| WO2020025942A1 (en) | 2018-07-30 | 2020-02-06 | NZP UK Limited | Fluorinated bile acid derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ298567A (en) * | 1994-11-23 | 2000-01-28 | Cocensys Inc | Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| FR2934596B1 (fr) * | 2008-07-30 | 2015-04-10 | Trophos | Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation |
| ITMI20121344A1 (it) * | 2012-07-31 | 2014-02-01 | Erregierre Spa | Processo di preparazione di acido ursodesossicolico ad elevata purezza |
| CN103333216A (zh) * | 2013-06-04 | 2013-10-02 | 苏州大学 | 5α-6-酮-胆甾烷类似物及其应用 |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
-
2018
- 2018-12-20 GB GBGB1820887.6A patent/GB201820887D0/en not_active Ceased
-
2019
- 2019-12-20 WO PCT/GB2019/053665 patent/WO2020128514A1/en not_active Ceased
- 2019-12-20 CA CA3123333A patent/CA3123333A1/en active Pending
- 2019-12-20 ES ES19831850T patent/ES3036094T3/es active Active
- 2019-12-20 AU AU2019411556A patent/AU2019411556B2/en active Active
- 2019-12-20 KR KR1020217019166A patent/KR102856276B1/ko active Active
- 2019-12-20 SG SG11202105465WA patent/SG11202105465WA/en unknown
- 2019-12-20 MX MX2021007551A patent/MX2021007551A/es unknown
- 2019-12-20 US US17/415,216 patent/US20220073557A1/en active Pending
- 2019-12-20 EP EP19831850.3A patent/EP3898645B1/en active Active
- 2019-12-20 CN CN201980085276.5A patent/CN113330020B/zh active Active
- 2019-12-20 JP JP2021535715A patent/JP7503063B2/ja active Active
- 2019-12-20 EA EA202191521A patent/EA202191521A1/ru unknown
- 2019-12-20 IL IL284093A patent/IL284093B2/en unknown
- 2019-12-20 BR BR112021011189-1A patent/BR112021011189A2/pt unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014036379A2 (en) | 2012-08-31 | 2014-03-06 | Metselex | Bile acids prevent or abolish progression of parkinson's and related neurodegenerative diseases |
| WO2016145216A1 (en) | 2015-03-10 | 2016-09-15 | Metselex, Inc. | Fluorinated and alkylated bile acids |
| WO2020025942A1 (en) | 2018-07-30 | 2020-02-06 | NZP UK Limited | Fluorinated bile acid derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| IL284093B1 (en) | 2025-03-01 |
| EP3898645C0 (en) | 2025-06-25 |
| AU2019411556A1 (en) | 2021-06-10 |
| WO2020128514A1 (en) | 2020-06-25 |
| IL284093A (en) | 2021-08-31 |
| EP3898645B1 (en) | 2025-06-25 |
| GB201820887D0 (en) | 2019-02-06 |
| KR20210125982A (ko) | 2021-10-19 |
| EP3898645A1 (en) | 2021-10-27 |
| CN113330020A (zh) | 2021-08-31 |
| ES3036094T3 (en) | 2025-09-12 |
| BR112021011189A2 (pt) | 2021-08-31 |
| JP2022514401A (ja) | 2022-02-10 |
| AU2019411556B2 (en) | 2025-04-03 |
| MX2021007551A (es) | 2021-10-13 |
| EA202191521A1 (ru) | 2021-09-10 |
| IL284093B2 (en) | 2025-07-01 |
| CN113330020B (zh) | 2024-04-05 |
| CA3123333A1 (en) | 2020-06-25 |
| US20220073557A1 (en) | 2022-03-10 |
| JP7503063B2 (ja) | 2024-06-19 |
| SG11202105465WA (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118027040A (zh) | 一种治疗冠状病毒感染的核苷类化合物及其用途 | |
| EP3105226B1 (en) | Cyclopropylamines as lsd1 inhibitors | |
| CN103119047B (zh) | 三环类蛋白酶体活性增强化合物 | |
| DE602004010708T2 (de) | Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen | |
| KR102856276B1 (ko) | 신경변성 질환의 치료를 위한 2-플루오린화된 담즙산 | |
| WO2017118375A1 (zh) | 地佐辛类似物 | |
| EP2699559B1 (en) | Dibenzothiazepine derivatives and their use in the treatment of cns disorders | |
| US20170119795A1 (en) | Fused triterpene compounds and uses thereof | |
| CN111620815B (zh) | 手性氯喹、羟氯喹和其衍生物及其制备方法与用途 | |
| EP3663299A1 (en) | Bicyclic compound acting as ror inhibitor | |
| US20120095071A1 (en) | 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom | |
| US20230159439A1 (en) | Arylamides and methods of use thereof | |
| US20250320246A1 (en) | 3-azasteroid compounds for the treatment of diseases related to mitrochondrial function | |
| PT97541B (pt) | Processo para a preparacao de indoles substituidos | |
| CN104860847A (zh) | 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物 | |
| EA046372B1 (ru) | 2-фторированные желчные кислоты для лечения нейродегенеративных заболеваний | |
| EP3186232B1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| HK40062202A (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| HK40062202B (en) | 2-fluorinated bile acids for the treatment of neurodegenerative diseases | |
| CN113620967B (zh) | 一种α-倒捻子素衍生物及其制备方法和应用 | |
| HK40086425A (zh) | 秋水仙碱衍生物的制备方法及其用途 | |
| JPH0641051A (ja) | フェノキシ酢酸誘導体 | |
| ITMI950804A1 (it) | Composti lattonici utili per il trattamento dell'osteoporosi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D13-X000 | Search requested |
St.27 status event code: A-1-2-D10-D13-srh-X000 |
|
| D14-X000 | Search report completed |
St.27 status event code: A-1-2-D10-D14-srh-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |